NSCLC - another juicy bite for Big Pharma!

From Here: NSCLC Therapeutics Market is Forecast to Show Moderate Growth Until 2017 The global NSCLC therapeutics market was valued at $4.5 billion in 2010 and is forecast to grow at a compound annual growth rate (CAGR) of 9.7% to reach $9.5 billion by 2018. This growth forecast is primarily attributed to the expected launch of Xalkori (crizotinib) by Pfizer in early 2012 for NSCLC patients with the ALK gene mutation. The rapid growth in market due to strong pipeline landscape, population growth, and the launch of new first-in-class drugs with better safety and efficacy profiles is slowed by and the patent expiry of currently marketed NSCLC products in the forecast period. Greater diagnosis at advanced stages and the availability of generics with satisfactory efficacy and safety profiles pose significant challenges for prospective market entrants.

Unmet Need Continues to Challenge Pipeline Drugs The prevailing market landscape will remain strong, with seven prominent drugs. These products offer improved efficacy over platinum drugs but none address all of the unmet need that exists in the NSCLC market. The current market provides significant potential for pipeline drugs that are stronger in terms of efficacy and safety. As patients become more aware of the latest technological developments, increased efficacy and safety profiles will be key factors that drive the acceptance and market penetration of pipeline products. As marketed products do not adequately serve unmet need, the market continues to offer opportunities for stronger pipeline candidates. However, considering the fact that most pipeline products are first-in-class, with proven efficacy in their therapeutic performance, existing market leaders will face significant challenges to maintain market share.